Adam P. Dicker, MD, PhD
Room G-301, Bodine Center
Philadelphia, PA 19107
(215) 503-0013 fax
Most Recent Peer-reviewed Publications
- β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1
- Phase I trials involving radiation therapy, quantifying the risks
- Impact of a radiation oncology elective on the careers of young physicians: Update on a prospective cohort study
- Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?
- ALK inhibitor PF02341066 (Crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK
Cornell University Medical College, New York, NY (MD) - 1992
Cornell University Graduate School of Medical Sciences, New York, NY (PhD) - 1991
Memorial Sloan-Kettering Cancer Center, New York, NY
American Cancer Society Clinical Oncology Fellowship, Memorial Sloan-Kettering Cancer Center, Department of Radiation Oncology, New York, NY
American Board of Radiology (Radiation Oncology): 1997, Recertified in 2000
Professor, Department of Pharmacology and Experimental Therapeutics (2010)
Jefferson Graduate School of Biomedical Sciences, Faculty Appointment in the Molecular Pharmacology and Structural Biology PhD Program (2011)
Research and Clinical Interest
Dr. Dicker is an international authority in Radiation Oncology, drug development and the treatment of prostate cancer and brain tumors.
Dr. Dicker co-leads the Radiation Research and Translational Biology Program at the Kimmel Cancer Center at Thomas Jefferson University. In addition, he serves as the Director of the Christine Baxter Research Laboratory for Experimental Cancer Therapies at Jefferson Medical College. Dr. Dicker has been a principal investigator in a significant number of “first in human” developmental therapeutic trials involving novel signal transduction agents and radiation therapy. He and his colleagues at Jefferson have developed new approaches to radiation therapy for the treatment of cancer, and have successfully applied their findings from the laboratory to the clinical setting.
Dr. Dicker serves as the Chair of the Translational Research Program in the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-sponsored cooperative group. He formerly served as Chair of the Radiation and Cancer Biology Committee of the American Society of Therapeutic Radiation Oncology. Dr. Dicker represents the RTOG on the National Cancer Institute’s Investigational Drug Steering Committee of Cancer Treatment Evaluation Program and also serves as a consultant on cancer to the European Commission, the National Cancer Institute of Canada and the Italian Association of Cancer Research. Dr. Dicker's reputation in research and clinical practice ranks him among Philadelphia Magazine’s “Top Docs” in Radiation Oncology and in Castle-Connolly America’s Top Doctors for Cancer. He has published extensively and has more than 150 peer-reviewed journal articles and chapters. Dr. Dicker serves on the editorial boards of Clinical Cancer Research, Cancer Biology, BMC Cancer and Radiation Oncology, and also provides reviews for eight additional journals as well.